Prime halts fraud in new claims process for COVID tests

The fraud, waste and abuse (FWA) prevention team identified and stopped a pharmacy that attempted to make fraudulent claims for at-home test kits

March 24, 2022

Earlier this winter, the team at Prime Therapeutics (Prime) developed a new claims process in just four days due to a federal mandate that required insurance companies to cover at-home COVID test kits.

With a major uplift like this, fraudsters oftentimes try to exploit gaps. But Prime’s fraud, waste and abuse (FWA) prevention team was prepared and had a plan ready.

Six days after the claims processing solution was implemented, Prime’s FWA analytics team identified its first case of fraud.

The pharmacy in-question submitted 411 claims from Jan. 21-24, 231 of which were for a specific brand of COVID test kits. Later, Prime learned that the pharmacy fraudulently submitted claims for nearly all the patients in their system. Prime contacted multiple patients, who denied ever requesting or receiving the kits. In one case, a member said the pharmacy billed tests to their insurance without permission.

As a result of the investigation, the pharmacy reversed all the tests they had billed, saving clients about $20,000 in claims and stopping the behavior within two weeks of it occurring.

Prime has since taken steps to terminate the pharmacy from its network.

“I am proud of the way Prime’s FWA prevention team handled this incident. While the savings that resulted from this investigation are significant, halting this behavior quickly is even more important,” says Mitchell Scott, director, special investigations unit. “This case is just one of many ways Prime’s team works to prevent FWA and protect our members.”

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion